Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

← catalyst calendar

NCT07409246 · readout ≤ 1,929 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
127estimated
Sites
11
Countries
China, Israel, Japan +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-02-27actualWhen the study began enrolling
Primary completionNov 2031estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionNov 2031estimatedThe whole study's end, after follow-up
First posted2026-02-13actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-14actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Multiple Myeloma

Intervention

  • Drug: ABBV-438

Primary outcomes

what the primary-completion date above is the date OF
Number of Participants With Adverse Events (AE)
measured Up to Approximately 69.5 Months
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
measured Up to Approximately 69.5 Months
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters
measured Up to Approximately 69.5 Months
Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)
measured Up to Approximately 69.5 Months

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed